DIGITAL HEALTH INTELLIGENCE REPORT COLLECTION
The Death of Cookie Targeting and the Future of Pharma Digital Advertising
While the demise of the 3rd-party cookie—the main enabler of personalized targeting on the Internet—has caused a great deal of anxiety for the digital advertising industry, it also opens up exciting new opportunities in the pharma sector.
Report Overview
Advanced medical wearables now comprise smart patches, smart rings, smart garments and smart ear buds and the emergence of validated medical-grade technology in consumer devices is seen as critical in delivering the next generation of wearables. Regulators are supportive and payers are seeing the contribution wearables can make to lowering the overall cost of health.
So, how can pharma benefit? In Innovations in Wearables for Digital Health digital health experts review the current wearables sector, examine the technologies that will shape the future and identify the challenges and areas of opportunity for pharma.
Key Therapies Covered
Bavencio (avelumab)
Keytruda (pembrolizumab)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Cabometyx (cabozantinib)
Fotivda (tivozanib)
Inlyta (axitinib)
Lenvima/Kisplyx (lenvatinib)
Sutent (sunitinib)
Votrient (pazopanib)
Afinitor (everolimus)
abexinostat
MK-6482
bempegaldesleukin
Content Highlights
- Subject synopsis
- Research methodology and objectives
- Key insights summary
- Issues and insights
What Our Clients Are Saying
“Excellent”
Director, Medical Affairs, AstraZeneca
“...this report has been very valuable”
Director, Biotech New Product Planning and Drug Delivery, Eli Lilly
Access This Discussion
Please complete the form below to listen to this discussion.
© 2021 FirstWord. All rights reserved | 1140 Avenue of the Americas, 14th Floor, New York, NY 10036
Partial List of Participating KOLs
Deputy Director
Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, Georgetown University School of Medicine, Washington, DC
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY
Professor
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Head of the Medical Oncology Department
Hospital Universitario Central de Asturias, Oviedo, Spain
Professor of Medicine
Head of the SS Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Professor of Oncology and Chief of the Oncology
Clinical and Translational Research Unit at Georges Pompidou Hospital, Paris, France
Our Research
We engage the world’s leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
Our in-house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
View A Full List Of Therapy Trends Reports
FirstWord’s FutureViews reports analyse in detail significant emerging technology and market trends that industry executives need to understand if they are to manage the opportunities and challenges that lay ahead.
Leading KOLS
KOL Answers
Future Focused
What Makes FirstWord FutureViews Reports Different?
Listen in: Expert Panel Discussion
Points covered
Expert Contributors
Horizon scanning
FutureViews reports explore in detail emerging developments that will shape future markets and business practice, helping you to identify threats and exploit emerging opportunities.
Knowledgeable experts
Contributors to FutureViews reports are carefully screened to ensure they are experienced subject experts whose insights on current trends and future developments are worth knowing.
Actionable insights
FutureViews reports take a 360-degree view of business-impacting trends and pinpoint the upcoming challenges so you can practically plan and develop response strategies.
Deep dive
Our research with industry experts results in hundreds of direct quotes, providing you with a first-hand, objective and comprehensive view of key market-shaping issues.
- Paying for Value
- Building on success of value-based approaches in health care
- Drug VBCs are a priority for some payers
- Choosing the right products
- Manufacturer competence needed for VBC
- Choosing the right payer to work with on a VBC
- VBCs can be offered at launch
- Technology is enabling VBCs
- Piloting VBCs
- Choosing the VBCs to publicize
- The challenges in scaling up use of VBCs
Each issue addressed is broken down into the following subsections
- Issue summary
- Questions
- Key insights
- Expert quotes
- Intelligence exhibits
Panelists
- Executive level experience in digital health, digital patient services or digital patient support with at least five years of involvement in digital health initiatives.
- At least three years’ experience in the field of digital health, mobile health, or digital capabilities for health.
- Direct experience designing, executing or influencing innovations in wearables for digital health initiatives in the last 18 months.
Jim Burke RPh, Head of Global Digital Marketing and Engagement, LEO Pharma
David Leitner, SVP Media, Klick Health
Sean Mario, SVP Revenue & Operations, WebMD Health
Moderator: Sheldon Gilbert, Founder & CEO, Proclivity Systems
- How does the removal of 3rd-party cookies impact HCP and DTC advertising in pharma?
- Will Google permit the use of pharma/healthcare related cohorts in their new FLoC and TURTLEDOVE protocols?
- How should pharma brands invest more in other first-party data personalized advertising channels such as email?
- How can medical publishers preserve their unique advantage over broader first-party platforms like Facebook, YouTube, and Amazon, by continuing to provide transparency around HCP and DTC engagement and reach for pharma brands?
- Joel Beilin, Founder and CEO of Global Audiology Consulting, Denmark
- Giovanni Di Sarro, Senior Business Partner of Global Digital Solutions at Lundbeck, Denmark
- Pierre-Alexandre Fournier, Co-founder of Hexoskin, a leading sensor and AI/analytics company for health, research and medicine
- Serkan Oray, Vice President of Devices, Packaging, & Wearable Technologies at UCB, Belgium
- Panos Papakonstantinou, Global Commercial Director of Mobility Solutions at the Novartis Institutes for BioMedical Research (NIBR), Switzerland
- Gergely Vértes, Solution Accelerator Lead and the Wearable Clinical Project Lead in Epilepsy at UCB Bekgium
- Dr. Jian Yang, Senior Director of Digital Health at Eli Lilly and Company, US
- Anonymous, technology leader, multinational biopharmaceutical company
Listen to this fascinating conversation where leading pharma digital advertising executives discuss what the future holds for digital HCP advertising. Learn why owners of first-party data stand to make gains, how digital DTC/patient advertising will be redefined, and how COVID, increased data privacy regulation, and new advanced data models and technology will usher in a new generation of digital advertising and data analysis. Key topics discussed include: